Suppr超能文献

槲皮素通过蛋白酶体-GSK-3 通路防止体内和体外心肌肥大。

Quercetin Prevents In Vivo and In Vitro Myocardial Hypertrophy Through the Proteasome-GSK-3 Pathway.

机构信息

Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Key Laboratory of Molecular Clinical Pharmacology and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, China.

Medical College of Jiaying University, Meizhou, 514031, China.

出版信息

Cardiovasc Drugs Ther. 2018 Feb;32(1):5-21. doi: 10.1007/s10557-018-6771-4.

Abstract

PURPOSE

Quercetin, a flavonoid, has been reported to ameliorate cardiovascular diseases, such as cardiac hypertrophy. However, the mechanism is not completely understood. In this study, a mechanism related to proteasome-glycogen synthesis kinase 3 (GSK-3) was elucidated in rats and primary neonatal cardiomyocytes.

METHODS

Rats were subjected to sham or constriction of abdominal aorta surgery groups and treated with or without quercetin for 8 weeks. Angiotensin II (Ang II)-induced primary cardiomyocytes were cultured with quercetin treatment or not for 48 h. Echocardiography, real-time RT-PCR, histology, immunofluorescence, and Western blotting were conducted. Proteasome activities were also detected using a fluorescent peptide substrate.

RESULTS

Echocardiography showed that quercetin prevented constriction of abdominal aorta-induced cardiac hypertrophy and improved the cardiac diastolic function. In addition, quercetin also significantly reduced the Ang II-induced hypertrophic surface area and atrial natriuretic factor (ANF) mRNA level in primary cardiomyocytes. Proteasome activities were obviously inhibited in the quercetin-treated group both in vivo and in vitro. Quercetin also decreased the levels of proteasome subunit beta type (PSMB) 1, PSMB2, and PSMB5 of the 20S proteasome as well as the levels of proteasome regulatory particle (Rpt) 1 and Rpt4 of the 19S proteasome. In particular, the PSMB5 level in the nucleus was reduced after quercetin treatment. Furthermore, phosphorylated GSK-3α/β (inactivation of GSK-3) was decreased, which means that GSK-3 activity was increased. The phosphorylation levels of upstream AKT (PKB (protein kinase B)) and liver kinase B1/AMP activated protein kinase (LKB1/AMPKα) and those of downstream extracellular signal-regulated kinase (ERK), histone H3, β-catenin, and GATA binding protein 4 (GATA4) were reduced after quercetin treatment, while hypertrophy was reversed after treatment with the GSK-3 inhibitor.

CONCLUSION

In summary, quercetin prevents cardiac hypertrophy, which is related to proteasome inhibition and activation of GSK-3α/β. Upstream (AKT, LKB1/AMPKα) and downstream hypertrophic factors, such as ERK, histone H3, β-catenin, and GATA4, may also be involved.

摘要

目的

槲皮素是一种类黄酮,已被报道可改善心血管疾病,如心肌肥大。然而,其机制尚不完全清楚。本研究在大鼠和原代乳鼠心肌细胞中阐明了与蛋白酶体-糖原合成激酶 3(GSK-3)相关的机制。

方法

将大鼠分为假手术组或腹主动脉缩窄手术组,并给予或不给予槲皮素治疗 8 周。用或不用槲皮素处理原代心肌细胞 48 小时,培养 Ang II。进行超声心动图、实时 RT-PCR、组织学、免疫荧光和 Western blot 检测。还使用荧光肽底物检测蛋白酶体活性。

结果

超声心动图显示,槲皮素可预防腹主动脉缩窄引起的心脏肥大,并改善心脏舒张功能。此外,槲皮素还显著降低了 Ang II 诱导的原代心肌细胞的心肌细胞肥大表面积和心钠肽因子(ANF)mRNA 水平。在体内和体外,槲皮素处理组的蛋白酶体活性均明显受到抑制。槲皮素还降低了 20S 蛋白酶体的蛋白酶体亚基β型(PSMB)1、PSMB2 和 PSMB5 以及 19S 蛋白酶体的蛋白酶体调节粒子(Rpt)1 和 Rpt4 的水平。特别是,槲皮素处理后核内 PSMB5 水平降低。此外,磷酸化 GSK-3α/β(GSK-3 失活)减少,表明 GSK-3 活性增加。用槲皮素处理后,上游 AKT(蛋白激酶 B(PKB))和肝激酶 B1/AMP 激活蛋白激酶(LKB1/AMPKα)的磷酸化水平以及下游细胞外信号调节激酶(ERK)、组蛋白 H3、β-连环蛋白和 GATA 结合蛋白 4(GATA4)的磷酸化水平降低,而用 GSK-3 抑制剂处理后心肌肥大得到逆转。

结论

总之,槲皮素可预防心脏肥大,这与蛋白酶体抑制和 GSK-3α/β 激活有关。上游(AKT、LKB1/AMPKα)和下游肥大因子,如 ERK、组蛋白 H3、β-连环蛋白和 GATA4,也可能参与其中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验